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Typhoid fever is still a global health problem, mainly in 
tropical and subtropical areas of the world and in devel- 
oping countries, where relatively elevated morbidity and 
mortality rates still are present, mostly because of per- 
sisting poor hygienic conditions. In the majority of 
Mediterranean regions, including Italy, the disease is con- 
stantly present, though with a low prevalence rate, as a 
result of an endemic persistence of Salmonella typhi 
infection.‘-* On the other hand, in industrialized coun- 
tries, most cases of S typhi infection are related to foreign 
travel or prior residence in endemic countries.4-6 In the 
United States, 2445 cases of typhoid fever have been 
reported in the decade 1985 to 1994, and the annual 
number of cases remained relatively stable over time: 
over 70% of episodes were acquired in endemic countries 
(mostly Mexico and India).6 
The persisting morbidity of S. typhi also may be sup- 
ported by the increasing resistance rate of this pathogen 
against a number of commonly used antimicrobial com- 
pounds. For instance, 6% of 331 evaluable S. typhi strains 
were resistant to ampicillin, chloramphenicol, and cotri- 
moxazole, and 22% of isolates were resistant to at least 
one of these three agents in a recent survey performed 
in the United States.’ The spread of antibiotic resistance 
among S. typhi isolates is emerging in many countries, and 
multidrug-resistant strains have been isolated, as well as 
isolates with poor susceptibility to fluoroquinolones,3-5z7-9 
so that in vitro susceptibility should be determined for 
all cultured strains, and antimicrobial treatment should 
be adjusted accordingly Nevertheless, fluoroquinolones 
(e.g., ciprofloxacin and pefloxacin) or third-generation 
cephalosporins, still represent the best choice for empir- 
ical treatment,z~4~6-sJ0 and mortality remains rare in West- 
ern countries (less than 1% of episodes), although it is 
expected to be greater in developing areas of the world. 
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The aim of this report is to describe two cases of typhoid 
fever that occurred in patients with human immuno- 
deficiency virus (HIV) infection, a rarely reported disease 
association in industrialized countries. 
CASE REPORTS 
Two male intravenous-drug users aged 34 and 41 years, 
with a prior diagnosis of acquired immunodeflciency syn- 
drome (AIDS) due to Pneumocystis carinii pneumonia 
and extrapulmonary cryptococcosis, respectively, were 
hospitalized because of prolonged irregular hyperpyrexia 
(lasting more than 1 week) preceded by chills and fol- 
lowed by abundant sweating. Toxemia, malaise, headache, 
and abdominal pain were the associated complaints, 
although no diarrhea or constipation were present. The 
second patient also had a faint maculopapular exanthema 
on the abdominal wall. From an epidemiologic point of 
view, the first patient spent the 2 months preceding 
hospitalization on a long trip in Southeastern Asia; the 
second one was homeless, experiencing long-term aban- 
donment, promiscuity, and poor hygienic conditions. A 
severe underlying immunodeficiency was documented 
by a CD4+ lymphocyte count of 34 and 7 cells&L, and 
an absolute neutrophil count of 1200 and 1650 cells/FL, 
respectively. Neither patient had undergone treatment 
with zidovudine or cotrimoxazole, in the weeks preced- 
ing hospital admission. Repeated blood cultures yielded 
S. typhi; stool and urine cultures tested negative. Later, 
Widal’s serum test proved positive in the first patient 
only (at a 1: 160 dilution). On the basis of the in vitro sus- 
ceptibility assay (showing a favorable activity of all tested 
compounds, including ampicillin, amoxicillin-clavulanate, 
piperacillin, cephalothin, ceftriaxone, ceftazidime, gen- 
tamicin, amikacin, netilmicin, chloramphenicol, cipro- 
floxacin, and cotrimoxazole), antimicrobial treatment was 
promptly started with intravenous cotrimoxazole (at 720 
mg of trimethoprim) in the first case, and intravenous 
piperacillin (4 g/d) in the second patient. Antibiotic ther- 
apy was carried out for 10 and 12 days, respectively. Both 
patients showed a slowly progressive improvement of 
disease signs and symptoms, and complete clinical and 
105 
106 International Journal of Infectious Diseases / Volume 3, Number 2, Winter 1998-1999 
microbiologic cure was obtained within 2 weeks, with- 
out complications or sequelae during the subsequent fol- 
low-up period. 
DISCUSSION 
Nontyphoid salmonellae are well recognized pathogens 
in the setting of HIV infection, and are mostly responsi- 
ble for recurring bacteremia, which may represent up to 
20% of episodes of bacterial septicemia in both adults 
and children with AIDS, with a particularly elevated 
incidence reported horn Africa and other developing 
countries. Salmonella enteritidis and Salmonella typhi- 
murium are the most common strains.11-18 The authors 
have reported an association of severe immunodeficiency 
and full-blown AIDS with bacteremia; bacteremia may 
occur in 76% of cases, and relapsing disease in 38%.19 
Because of its significant morbidity and relation with 
advanced HIV infection, nontyphoid salmonellosis has 
been included in the list of AIDS-defining diseases since 
1987. The annual incidence of nontyphoid salmonellosis 
has been estimated to be lo- to loo-fold greater in 
HIV-infected individuals, compared with the general pop- 
ulation.ll,l* A low CD4+ lymphocyte count, concurrent 
opportunistic infections, alterations in intestinal mucosa, 
perianal ulcers, and prior use of broad-spectrum anti- 
biotics, represent important risk factors.13-16J9 Dissemi- 
nated disease sometimes leads to suppurative or focal 
complications (including endocarditis, meningitis, cel- 
lulitis, arthritis, myositis, pneumonia, and urinary tract 
infection),l*~17,18,20-22 b u gastrointestinal complaints are t 
relatively infrequent, and Salmonellae may be isolated 
from stools in less than 20% of bacteremic patients. Even 
though antibiotic resistance of nontyphoid Salmonellae 
is increasing worldwide,8J4 quinolones, third-generation 
cephalosporins, as well as cotrimoxazole and ampicillin 
are still effective, and the mortality rate remains 
1ow.8~10~11~‘3-15~17-19 However, long-term suppressive chemo- 
therapy is recommended to avoid recurrences. Cotri- 
moxazole (widely employed as a prophylactic agent for 
both AIDS-related pneumocystosis and toxoplasmosis) 
and zidovudine (which is effective against Salmonella 
spp) have been shown to significantly reduce both occur- 
rence and relapse of nontyphoid salmonellosis in patients 
with HIV disease.23-z5 
Salmonella typhi complications infrequently have 
been reported in HIV-infected patients, mostly in indus- 
trialized countries. In fact, most cases of HIV-associated 
typhoid fever have been described in the developing 
regions of the world, where both S. typhi and HIV infec- 
tion are endemic.12J6J6-29 In Africa, the frequency and clin- 
ical features of HIV-associated S. typhi infection do not 
differ from those encountered in the general population, 
when a possible higher rate of focal complications is 
excluded.12J6,26-28 In particular, two cases have been 
reported in a comprehensive series of HIV-related bac- 
teremia from Kenya, where the estimated frequency of 
typhoid fever among patients with HIV disease was sim- 
ilar to that observed in a control group of non-HIV- 
infected subjects with septicemia; both isolated S. typbi 
strains appeared sensitive to all tested antibiotics, and both 
patients were cured.26 In a series from Ivory Coast, only 
one case of typhoid fever was reported, caused by a strain 
that tested sensitive to all antibiotics. The global preva- 
lence of HIV-associated disease is lower than that observed 
among patients without HIV infection.12 Another case of 
S. typbi bacteremia involved an HIV-infected woman from 
Zimbabwe, and was complicated by common iliac artery 
occlusion.27 In a second report, from Ivory Coast, a patient 
was described, and a similar prevalence of typhoid fever 
among HIV-positive and HIV-negative subjects was con- 
firmed.‘” The largest clinical series recently described from 
South Africa reported 10 cases of typhoid fever among 
subjects with asymptomatic HIV infectionz8 Fever, tox- 
emia, and relative bradycardia were the most common 
clinical features; diarrhea was reported in four cases; and 
there was a lethal outcome in two. When compared with 
a control group of non-HIV-infected individuals, patients 
with underlying HIV disease did not show different epi- 
demiologic or clinical features, when an increased risk of 
liver and kidney involvement was excluded.28 Finally, an 
early report from Gotuzzo et a1,29 describing six cases of 
typhoid fever and two additional patients with Salmo- 
?zel.Za pamtyphi infection complicating HIV disease in 
Peru, pointed out a typical clinical presentation and favor- 
able therapeutic response in the four patients with asymp- 
tomatic or mildly symptomatic HIV disease, whereas the 
remaining four individuals with full-blown AIDS experi- 
enced severe intestinal complications (fulminant diarrhea, 
enterocolitis, or rectal ulcerations) and frequent relapses, 
despite therapeutic attempts with chloramphenicol, amox- 
icillin, norfloxacin, and ceftriaxone.29 Only this last clini- 
cal report showed a significantly increased risk of typhoid 
fever among HIV-infected patients, associated with an 
apparently increased disease severity and mortality.29 The 
estimated overall incidence was about 60 times greater 
than in the general population. 
To the authors’ knowledge, only five cases of HIV- 
associated S. typhi infection have been reported to date 
from developed countries.“,30-33 The first one from Lon- 
don, was described in 1986 in an homosexual male with 
a CD4+ lymphocyte count of 200 cells&L and no his- 
tory of travel in endemic regions; despite disseminated 
infection (with positive blood, stools, and bone marrow 
cultures) and one relapse, typhoid fever was successfully 
treated with chloramphenicol, later combined with amox- 
icillin.‘O A second case was reported 5 years later, in a 
series from Italy, and involved an adult patient with dif- 
fuse HIV-related lymphadenopathy; details regarding clin- 
ical picture, treatment, and outcome are lacking.‘l In 
1992, one case of S. typhi bacteremic pneumonia was 
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reported from the United States in a Hispanic patient 
with AIDS with prior lung tuberculosis and concurrent 
Kaposi’s sarcoma and disseminated mycobacteriosis and 
without a recent history of travel abroad.31 However, S. 
typhi was not isolated from respiratory secretions, and 
Widal’s serology tested negative.31 In the same year 
(1992), in the United States one case of S. typhi post-trau- 
matic splenic abscess was described in an HIV-infected 
intravenous-drug user who underwent splenorrhaphy; 
ampicillin administration and splenectomy led to com- 
plete remission.32 The last known case was reported, 
again from the United States, in 1995, and described an 
intrapartum chorioamnionitis caused by S. typbi in a preg- 
nant HIV-infected woman. Maternal blood, cervical, uter- 
ine, and placental cultures grew the pathogen, but 
response to antibiotic therapy was favorable, without 
relapse, or involvement of the infant.33 
Both clinicians and microbiologists should be aware 
of the possible occurrence of S. typhi complications 
among immunocompromised patients with HIV disease, 
even in developed countries. According to the authors’ 
experience, in the United States, the clinical picture and 
outcome of AIDS-associated typhoid fever do not show 
significant differences from those reported from non- 
HIV-infected patients. However, an association with-far- 
advanced HIV disease and full-blown AIDS was demon- 
strated, as well as failure of specific serodiagnosis, as in 
a previously reported patiem31 possibly owing to the 
concurrent severe immunodeficiency. A careful evalua- 
tion of medical history and epidemiologic features may 
play a key role in prompting search for a S. typhi infec- 
tion, especially in patients coming from endemic regions 
or living with poor hygiene and promiscuity, since the 
majority of signs and symptoms of typhoid fever mimick 
those of any sepsis, or other AlDS-related complications. 
In fact, international travel has been reported as a risk 
factor for exotic or imported infectious complications in 
patients with HIV disease,34 so that information, precau- 
tions in handling food and beverages, and immunization 
should be recommended to anyone planning to travel in 
endemic countries. Because of the increasing frequency 
of antimicrobial resistance of S. typhi strains worldwide, 
in vitro susceptibility testing should be performed to 
guide antimicrobial treatment. The authors found all 
tested compounds to be active against cultured organ- 
isms, and cotrimoxazole or piperacillin administration 
proved clinically effective. 
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